REVIEW

The pathophysiology and treatment of delayed cerebral ischaemia following subarachnoid haemorrhage

Karol P Budohoski,1 Mathew Guilfoyle,1 Adel Helmy,1 Terhi Huuskonen,1,2 Marek Czosnyka,1 Ramez Kirolos,1 David K Menon,3 John D Pickard,1 Peter J Kirkpatrick1

ABSTRACT
Cerebral vasospasm has traditionally been regarded as an important cause of delayed cerebral ischaemia (DCI) which occurs after aneurysmal subarachnoid haemorrhage, and often leads to cerebral infarction and poor neurological outcome. However, data from recent studies argue against a pure focus on vasospasm as the cause of delayed ischaemic complications. Findings that marked reduction in the incidence of vasospasm does not translate to a reduction in DCI, or better outcomes has intensified research into other possible mechanisms which may promote ischaemic complications. Early brain injury and cell death, blood-brain barrier disruption and initiation of an inflammatory cascade, microvascular spasm, microthrombosis, cortical spreading depolarisations and failure of cerebral autoregulation, have all been implicated in the pathophysiology of DCI. This review summarises the current knowledge about the mechanisms underlying the development of DCI. Furthermore, it aims to describe and categorise the known pharmacological treatment options with respect to the presumed mechanism of action and its role in DCI.

INTRODUCTION
The incidence of spontaneous subarachnoid haemorrhage (SAH) is around 6–11 per 100 000 persons per year.1,2 Due to the relatively young age of the affected population and the high rates of disability, the burden to society is high, with a reported loss of productive years similar to ischaemic and haemorrhagic strokes.3

Over the past two decades, the advancement of understanding of the pathophysiology of SAH and its sequelae has led to a considerable reduction in the mortality.4 Data suggest that this reduction may be related to new management protocols directed at early aneurysm repair, and aggressive management of acute hydrocephalus and delayed cerebral ischaemia (DCI).4,5 Despite these advances, about 30% of patients who survive following SAH will not regain full independence,6 while 69% will report a reduced quality of life.7

DCI is recognised as one of the leading causes of unfavourable outcome following SAH.8 Understanding the exact mechanisms which lead to DCI is important in the development of new treatment strategies. Furthermore, with multiple therapies being tested, it is important to understand the background behind the interventions, as well as the current state of evidence for their likely benefit.

DCI
DCI has been shown to occur in 30–40% of patients with SAH.8–11 The pathophysiology of DCI is complex and not fully understood. Until recently, the prevailing view has been held that there is a direct link between arterial narrowing seen on angiography and clinical symptoms of brain ischaemia. However, recent data argue that this relationship is inconsistent. While angiography and perfusion imaging often demonstrate vasospasm and associated perfusion deficits, this is by no means invariable, and in many cases, DCI may be a diagnosis of exclusion without clear radiological findings.

CEREBRAL VASOSPASM
Ecker and Riemenschneider12 first documented the presence of cerebral vasospasm (CVS) in relation to a ruptured aneurysm. Allcock and Drake13 demonstrated a link between vasospasm and symptoms of focal ischaemia. Arterial narrowing has typically been shown to have a delayed onset and a peak between 5 and 14 days, following which it typically resolves (figure 1).14–18 It is, therefore, understandable as to why CVS has been related to delayed deterioration.14–18

Multiple signalling pathways have been implicated in the pathogenesis of arterial spasm. The principal initiating factors are thought to be blood degradation products which accumulate in the subarachnoid space and act as triggering substances for the development of endothelial dysfunction and an intramural inflammatory response.

Blood degradation products
Clinically, there is a clear link between the severity of CVS and the amount of subarachnoid blood seen on CT,19–23 a relationship recognised by the Fisher scale.19 The contractile property of cerebrospinal fluid (CSF) from patients with SAH was first described by Buckell.24 Since then it has been demonstrated that blood degradation products trigger a molecular cascade which leads to CVS. Several key observations support the role of oxyhaemoglobin, in particular, in the pathogenesis of post-SAHI
vasospasm. It was shown to induce vasoconstriction in cerebral arteries in vitro.\textsuperscript{23-27} Furthermore, intrathecal injection of oxyhaemoglobin, or a supernatant from autologous blood, was shown to induce vasospasm in primates. Importantly, in the same experiment, injection of methaemoglobin, bilirubin or sham CSF did not induce vasospasm. The exact mechanisms by which oxyhaemoglobin induces vasoconstriction remain unknown, but several key factors have been described. Oxyhaemoglobin is known to alter the synthesis of eicosanoids in vessel walls, in particular, decrease the production of PGI\textsubscript{2} and increase the production of PGE\textsubscript{2}. Furthermore, oxyhaemoglobin spontaneously oxidises to methaemoglobin releasing superoxide, which in turn, is known to lead to lipid peroxidation and vasoconstriction. Finlay, it has been demonstrated that oxyhaemoglobin inhibits endothelial-dependent relaxation.\textsuperscript{24} However, experimental and clinical studies have not, so far, demonstrated that inhibition of any one of these mechanisms alone can completely reverse vasospasm, further confirming a multidirectional effect of blood degradation products on cerebral vasculature. At present the molecular pathways remain largely unknown, and there are no effective pharmacological means to influence all the implicated mechanisms. However, approaches aimed at clearing subarachnoid spaces form blood products seem reasonable.

Inflammation

Blood-brain barrier breakdown as a consequence of SAH has been shown to lead to trafficking of lymphocytes into the CSF, as well as infiltration of arterial walls.\textsuperscript{28-31} While little direct evidence exists confirming that an induced inflammatory process may directly lead to development of vasospasm, it has been demonstrated that activated mononuclear cells within the CSF can release ET-1, a known vasoconstricting agent.\textsuperscript{32} Furthermore, blood degradation products were shown to be sufficient to induce ET-1 production by activated mononuclear cells providing a direct link between SAH, inflammation and ET-1 production.\textsuperscript{32} Longitudinal analysis of the inflammatory reaction after SAH revealed that there is a massive, compartmentalized increase in the secretion of proinflammatory cytokines such as IL-1\textbeta and IL-6.\textsuperscript{33} Furthermore, the changes in cytokine concentrations parallel the changes in blood flow velocity.\textsuperscript{33}

Nitric oxide and nitric oxide synthase

Nitric oxide (NO) is one of the key endothelium-derived factors which govern vascular muscle tension. It increases 3', 5'-cyclic guanosine monophosphate (cGMP) levels in vascular smooth muscle cells leading to vasodilatation and an increase in cerebral blood flow.\textsuperscript{34-35} NO levels are known to decrease following SAH in a characteristic biphasic distribution: acute—30 min after the ictus;\textsuperscript{36} and delayed—around 4–7 days following the ictus.\textsuperscript{37, 38} Whether, this is a result of binding by oxyhaemoglobin or secondary to an inflammatory process remains unknown. Furthermore, while shear stress induces vasodilatation in healthy arteries via endothelial NO synthase (NOS), this pathway is impaired following SAH,\textsuperscript{39, 40} with a clear reduction in NOS mRNA reported on day 7 post-ictus.\textsuperscript{41} Furthermore, endogenous inhibitors of endothelial NOS, such as asymmetric dimethylarginine and protein kinase C have been described to be upregulated following SAH.\textsuperscript{42-44} Experimental and human data suggest that vasospasm can be ameliorated with the aid of exogenous NO donors such as sodium nitroprusside or nitroglycerine.\textsuperscript{45, 46} However, adverse systemic effects of these medications (principally hypotension, which has been shown to be more pronounced than that seen with nimodipine) make them inappropriate for routine systemic administration in clinical practice. Nevertheless, it needs to be pointed that a number of studies have investigated intrathecal administration of NO donors in humans with little systemic side effects. However, the deactivation of NO exposed to oxyhaemoglobin and deoxyhaemoglobin, (formation of methaemoglobin, S-nitroso-haemoglobin and ferrous-nitrosyl-haemoglobin) remains a concern (see Pluta\textsuperscript{47} for a detailed review on NO and DCI). Recently the safety of systemic administration of sodium nitrate in humans has been confirmed, with potential clinical trials in SAH awaited.\textsuperscript{48}

Endothelin-1

Endothelin-1 (ET-1), one of the most potent endogenous vasoconstrictors, produced by endothelial cells, is stimulated by ischaemia insult, but also by oxyhaemoglobin.\textsuperscript{49} The levels of ET-1 in the CSF of patients with vasospasm have been shown to be higher than those found in healthy subjects.\textsuperscript{50, 51} Furthermore, increases in ET-1 levels correlate with the onset of ischaemic symptoms.\textsuperscript{50, 51} However, other studies demonstrated that, although, ET-1 levels were higher in patients with DCI, they were within normal range in patients with angiographic evidence of arterial narrowing without clinical symptoms,\textsuperscript{52} suggesting that ET-1 may be a marker of ischaemic tissue damage rather than vasospasm.\textsuperscript{52} While the exact role of ET-1 in the development of CVS is unknown, it has been demonstrated that administration of ET-1 receptor type A (ETA) antagonists in an experimental setting reduced vasospasm.\textsuperscript{53, 54} Similar findings were reported in the randomised controlled trial of Clazosentan (an ETA receptor antagonist), where inhibition of ET-1 signalling significantly reduced large vessel narrowing in a clinical setting.\textsuperscript{55-59}

THE RELATIONSHIP BETWEEN VASOSPASM AND DCI

Narrowing of cerebral arteries may cause a reduction of cerebral blood flow distal to the spastic segment, depending on the state of autoregulation, which in consequence, may lead to ischaemia and infarction.\textsuperscript{60-63} However, while up to 70% of patients demonstrate a degree of arterial narrowing on catheter angiography,\textsuperscript{64-65}...
only 20–30% develop clinical symptoms. The positive predictive value of vasospasm (diagnosed using stringent criteria with the aid of two imaging methods) for DCI is only 67%. Furthermore, up to 25% of delayed infarcts seen on follow-up CT are not located in the territory of the spastic artery, or are found in patients who did not demonstrate vasospasm.

A number of studies suggested that only severe vasospasm with at least 50% luminal narrowing produces a reduction of cerebral blood flow which is sufficient to cause symptoms of ischaemia. However, others have reported that only 50% of patients with severe CVS on angiography become symptomatic. Positron emission tomography (PET) has shown that delayed neurological deficits after SAH were associated with a wide range of haemodynamic disturbances, ranging from hypoperfusion to hyperaemia, and that the spatial distribution of the haemodynamic disturbances did not always coincide with the vascular territory where narrowing was identified. With a more widespread use of perfusion imaging methods (such as perfusion CT) for the evaluation of DCI, similar findings are being increasingly reported (figure 2).

By contrast, some studies, with rigorous angiographic control, report that indeed, there is a significant correlation between angiographic vasospasm, DCI and delayed infarctions on follow-up imaging, and that only 3% of patients with none or only mild angiographic spasm develop delayed infarcts. These findings spark the question, whether other factors may responsible for the observed discrepancies. It is known that transcranial Doppler (TCD) diagnosis of vasospasm is limited mainly to the anterior circulation and, in particular, to the middle cerebral artery, therefore, spasm in other vessels may be misinterpreted. Furthermore, infarction on follow-up imaging needs to be interpreted with caution in the absence of immediate postoperative imaging to rule out other, potentially iatrogenic causes. As immediate postoperative imaging is not standard practice in many centres, this is not always reported. While in most cases, SAH is promptly diagnosed and the culprit aneurysm detected and treated, there remains a population of patients with a delayed presentation with only minimal symptoms who may have been exposed to haemodynamic instability in the early phase post-bleed.

Nevertheless, a recent meta-analysis of pharmacological treatment of vasospasm and DCI demonstrated that, despite a reduction in the incidence of CVS, there was, in most cases, little or no effect on outcome. Similar results were reported from the trial of clazosentan (a potent ETA receptor antagonist) as well as nicardipine (potent calcium channel blocker). Conversely, n nimodipine, which is so far, the only drug for which class I evidence exists, reduced the incidence of DCI and poor outcome by 40%, without ameliorating vasospasm.

While many of the disappointing results may have been a consequence of systemic complications of the investigated compounds, which often caused blood pressure instability or pulmonary complications (such as those observed in trials of clazosentan and nicardipine), together these results argue against arterial narrowing being the sole cause of DCI. Given these findings, there is a clear need to investigate other mechanisms which may promote cerebral ischaemia following SAH. These include early brain injury (EBI), microvascular spasm, microthrombosis, spreading cortical depolarisations and failure of cerebral autoregulation (figure 3).

**EARLY BRAIN INJURY**

Recent reports suggest that events occurring before the onset of vasospasm, during the first 72 h after the ictus may significantly contribute to outcome following SAH. EBI includes the primary injury resulting from the ictus as well as its direct consequences.

It has been demonstrated in experimental and clinical studies that aneurysm rupture is accompanied by a severe rise of intracranial pressure, often to suprasystolic levels, caused by extravasation of arterial blood into the subarachnoid spaces, as well as a vasodilatory cascade. Intracranial hypertension leads to a decrease in cerebral perfusion pressure, and ultimately to cessation of cerebral blood flow (clinically manifested as syncope or loss of consciousness), and in consequence, global ischaemia, and later oedema. Another mechanism which leads to increases of intracranial pressure and reductions of cerebral blood flow is CSF outflow obstruction and acute as well as chronic hydrocephalus. Hydrocephalus may also contribute, at least partially, to the early haemodynamic disturbances and, hence, EBI.

---

**Figure 2** (A) Cerebral angiogram of a patient with WFNS 1, Fisher 3 SAH from a ruptured left PComA aneurysm (left ICA injection) performed on day 6 postictus, demonstrates diffuse severe vasospasm in the left ICA, ACA and MCA. (B) Perfusion CT performed same day shows mild reduction in CBF with (C), a compensatory increase in CBV indicative of autoregulatory vasodilatation. (D and E) CT on day 12 demonstrates delayed infarcts in the ACA and MCA territories. (F) Cerebral angiogram of a patient with WFNS 2, Fisher 3 SAH from a ruptured right AChA aneurysm (right ICA injection) performed on day 8 postictus, demonstrates segmental vasospasm in the right ICA and MCA, as well as diffuse vasospasm in ACAs bilaterally. (G and H) Perfusion CT scan performed on the same day, demonstrates a perfusion deficit only in the left ACA territory only in CBF and CBV. (I and J) Delayed CT did not demonstrate any hypodensities. ACA, anterior cerebral artery; AChA, anterior choroidal artery; CBV, cerebral blood flow; CBV, cerebral blood volume; ICA, internal carotid artery; MCA, middle cerebral artery; SAH, subarachnoid haemorrhage; WFNS, World Federation of Neurosurgical Societies.

Global cerebral ischaemia, which occurs in the acute phase of SAH, has been shown to activate several key pathophysiological pathways which, in consequence, may lead to direct nervous tissue injury as well as increased tissue vulnerability to secondary insults. These include initiation of cell death mechanisms, blood-brain barrier disruption, an acute inflammatory response, all of which contribute to development of cerebral oedema, which itself is a poor prognostic factor. Furthermore, the acute haemodynamic compromise may lead to microvascular spasm and thrombosis, as well as failure of cerebral autoregulation (figure 3). All these processes are potential players in perpetuating ischaemic injury after SAH, potentially contributing to the delayed manifestation when sufficient insults have occurred. The mechanisms implicated in DCI, along with the relevant publications are summarised in online supplementary table S1.

**Figure 3** Diagram depicting the possible pathophysiological pathways which may lead to development of DCI. The time ranges at bottom depict approximate/presumed periods when the various processes occur. At present, it is unknown which of the mechanisms is the main culprit, however, the paradigm is shifting away from cerebral vasospasm. AIF, apoptosis inducing factor; CBF, cerebral blood flow; CBV, cerebral blood volume; EDHF, endothelial derived hyperpolarising factor; ET-1, endothelin 1; FasL, Fas ligand; ICP, intracranial pressure; IL-6, interleukin 6; NO, nitric oxide; NOS, nitric oxide synthetase; Oxy-Hb, oxyhaemoglobin; PAF, platelet-activating factor; PGI2, prostacycline; TNFR, tumour necrosis factor receptor; vWF, von Willebrand factor; DCI, delayed cerebral ischaemia. (Based on refs. 90, 94, 95, 99).

**Oxidative Stress**
Experimental and clinical evidence exist supporting the role of free radicals and oxidative stress in SAH. Generation of free radicals is related to auto-oxidation of haemoglobin in the CSF, altered mitochondrial function, lipid peroxidation, as well as NADPH oxidase function. Studies showed that generation of free radicals is important in the pathogenesis of CVS as well as DCI. Human data indicates an increase in oxidative stress and lipid peroxidation in serum as well as CSF within 3 days after SAH. Furthermore, the increases are more pronounced in patients who developed DCI and those with poor neurological outcome. Markers of CSF lipid peroxidation peaked at day 6, suggesting a temporal relationship with DCI. However, due to the lack of simultaneous clinical correlation it is difficult to judge whether they precipitated of were a consequence of ischaemia. Nevertheless, in transgenic animal models it was demonstrated that an increase in the antioxidant capabilities leads to a reduction in apoptotic cell death after SAH.

**Cell Death, Blood-Brain Barrier Breakdown and Inflammation**
Experimental data looking at cell death mechanisms is largely derived from experimental animal work due to the difficulty with available technology to image these processes in vivo. It has been demonstrated that neuronal cell death occurs within 24 h after SAH. Necrosis, apoptosis and autophagy have all been described in animal models, often simultaneously. Intrinsic, caspase-dependent pathways have been shown to be activated as early as 40 min after SAH. Activation of proapoptotic proteins, such as Bak, Bax, Bad and Bel- XS is associated with unfavourable outcome, vascular spasm, as well as hyperthermia.

**Microvascular Spasm**
A study by Yundt et al demonstrated a diminished vasodilatory capacity of the cerebral microcirculation in patients who sustained SAH. Furthermore, data from experimental studies, where direct observations of small intraparenchymal and pial arterioles was performed, suggested the presence of microvascular spasm in two different experimental models of SAH. Oikuma et al performed serial morphometric analyses of cerebral microvessels after cisternal blood injection, and demonstrated maximal luminal narrowing between days 3 and 7.
Similar findings were reported in vivo in mice subjected to experimental SAH. In vivo microvascular spasm assessed using the cerebral circulation time on angiography showed that if present within the first 24 h, it might be predictive of subsequent large vessel vasospasm and DCI. Furthermore, it was demonstrated that regional reductions in cerebral blood flow are better correlated with narrowing in the microvascular compartment than with narrowing of large cerebral arteries. These observations argue that microvascular constriction, or the lack of microvascular dilatation may play a role in the development of DCI. The presence of microvascular spasm, not readily visible on catheter angiography, or transcranial Doppler may account for the observed discrepancies between imaging and clinical symptoms.

**MICROTHROMBOSIS**

It has been shown that the levels of blood coagulation markers correlate with development of DCI. Procoagulant activity has been shown to precede DCI, with increased levels of platelet-activating factors noted on day 4 post-SAH, an increase in the von Willebrand factor seen as early as 72 h after the ictus, and loss of collagen type IV (a component of the basal lamina). These changes were accompanied by platelet aggregation in parenchymal vessels, which was seen as early as 10 min after experimental SAH. Interestingly, the timing of aggregate clearance is inconsistent with one study reporting reperfusion at 24 h, while in another, the peak intensity of platelet aggregation at the same time point. Importantly, microthrombi have also been found on autopsy of patients with SAH confirming that microthromboemboli are indeed a part of the clinical picture following SAH, in humans.

Antifibrinolitic therapy with tranexamic acid resulted in a significant reduction in the rate of rebleeding following SAH. However, the benefit may have been counteracted by the increased incidence of DCI, which was not associated with large vessel spasm. These findings lead researchers to believe that the changes in coagulation homeostasis induced by tranexamic acid (causing microthrombosis) may have promoted DCI.

A large systematic review and a meta-analysis performed by Darhour Mees and colleagues demonstrated that administration of antiplatelet medications after SAH reduces the relative risk (RR) of DCI by 15%, and shows a non-significant trend towards improved outcomes. Nevertheless, a benefit on outcome was not demonstrated, hence routine use is not recommended.

**CORTICAL SPREADING DEPOLARISATION**

Cortical spreading depolarisation is an abrupt electrical change with near-complete and sustained depolarisation of a neuron or group of neurons, which has a tendency to spread through the cortex, and is associated with hyperaemia. However, when clustered or affecting injured tissue cortical spreading depolarisations are associated with metabolic, biochemical and morphological dysfunction of brain parenchyma, manifested as hyperperfusion, cytotoxic oedema and hypoxia. Cortical spreading depressions do not normally occur in uninjured brain, however, they have been implicated in the pathophysiology of migraine. Spreading depolarisations have been observed in poor grade patients following SAH.

A multicenter observational study where invasive electrocorticography was performed, the CoOperative Study on Brain Injury Depolarisations (COSIBID) demonstrated that clusters of spreading depolarisation are associated, and precede, development of DCI in the absence of vascular spasm. The proposed mechanism responsible for propagation of DCI in these cases is thought to be an inverted haemodynamic response. In normal circumstances, a wave of spreading depolarisation is accompanied by a hyperaemic response. With repeated waves, this haemodynamic response is diminished, and a vasoconstrictive reaction is observed with a decreased regional cerebral blood flow and oxygen supply. The mechanism for the inverted haemodynamic reaction remains poorly understood. In particular, it is unclear whether the mechanism responsible for vasoconstriction and vasodilatation during waves of depolarisations are the same as for vasomotor reactions in response to chemical and pressure stimuli.

**CEREBRAL AUTOREGULATION**

Experimentally, CVS does not reduce distal cerebral blood flow unless there is an additional insult, such as a fall in blood pressure. This finding supports Harper’s dual-control hypothesis, whereby proximal arterial spasm may be compensated by distal autoregulatory vasodilation. However, there is a limit to such compensatory mechanisms, which is why a second insult, such as a drop in perfusion pressure or increased metabolic needs, results in insufficient blood and nutrient supply leading to ischaemia. With impaired autoregulatory mechanisms (figure 4), even a single insult, such as vessel narrowing or haemodynamic instability, may lead to significant drop in blood flow rendering the brain at an increased risk of ischaemia. Evaluation of cerebral autoregulation is being increasingly recognised as a factor requiring consideration in the management of patients with SAH. Three recent prospective studies have demonstrated that indirect indices of cerebral autoregulation can be used to prognosticate DCI as well as long-term outcome after SAH. Importantly, autoregulation was found to deteriorate before clinical symptoms as well as radiographically identifiable arterial narrowing. Whether treatment interventions can be used to alter the state of autoregulation is unknown.
study of 80 patients, it was demonstrated that treatment with pravastatin shortens the duration of autoregulatory impairment. While a reduction in vasospasm and DCI was also observed, there was no effect on 6-month outcome.

TREATMENT OF DCI
DCI, where insufficiency of blood and nutrient supply to the brain is present, may in consequence lead to infarction, permanent deficits and ultimately poor functional outcome. Despite the multiple mechanism involved, therapy has been largely targeting large vessel spasm. The following sections aim to summarise the current treatment strategies, for which human data is available. The available randomised controlled trials RCTs are delineated in online supplementary table 2.

Clearance of subarachnoid spaces
Blood degradation products are thought to be one of the principal mechanisms responsible for development of vasospasm, suggesting that rapid clearance of blood from subarachnoid spaces may have beneficial effects. Numerous methods have been investigated, including continuous cisternal drainage, lumbar drainage, as well as intrathecal administration of thrombolitics. There are reports suggesting good success rates in decreasing the incidence of DCI with continuous cisternal drainage, however, a RCT has not been performed. Results from the first single-centre trial of early, continuous lumbar drainage hold promise, with a significant decrease in the incidence of DCI from 35% to only 21%. However, the study failed to demonstrate any long-term benefit in outcome. Another trial aiming to recruit 300 patients is currently ongoing (clinicaltrials.gov; NCT01258257).

Five RCTs have evaluated the use of intrathecal thrombolytic agents to clear subarachnoid blood. A meta-analysis of these studies suggests a reduction in the incidence of DCI, as well as improvements in outcome. However, the benefit failed to reach statistical significance after exclusion of one study where concomitant intrathecal nimodipine was administered.

Systemic targeting of angiographic vasospasm
Nimodipine, a calcium channel blocker, is the only drug approved for use in SAH, and is the mainstay of treatment. In a meta-analysis, it has been shown to reduce the risk of poor outcome, with a RR of 0.7. While traditionally nimodipine has been thought to prevent CVS, vascular narrowing on angiography was not included as an outcome measure in the largest trial. Other RCTs have demonstrated that nimodipine does not have an effect on angiographic vasospasm despite the beneficial effect on outcome, suggesting a different mechanism. In vitro and in vivo research demonstrates that nimodipine may have an effect on the whole vasculature, inhibiting contractions induced by noradrenaline and serotonin, potassium membrane depolarisation, as well as PGF2α/β. Furthermore, nimodipine has been also described to increase the fibrinolytic activity by decreasing the level of plasminogen activator inhibitor-1 (PAI-1).

Nicardpine has been evaluated in a large, multicenter RCT in the USA—Cooperative Aneurysm Study. The advantage of nicardpine was the ease of preparation of the intravenous formula to be administered continuously. The study demonstrated a significant reduction of vasospasm from 46% to 32%. However, there was no benefit on outcome, with an increased number of systemic complications, such as pulmonary oedema and metabolic derangements in the treatment group.

Another vasodilator which has been studied in SAH is fasudil. Fasudil is a potent RhoA/Rho kinase (ROCK) inhibitor, which is also thought to inhibit the action of free intracellular calcium, as well as inhibit protein kinases A, G and C, and myosin light-chain directly. Fasudil has been repeatedly shown to have beneficial effects on development of CVS, delayed cerebral infarcts as well as outcome. Furthermore, fasudil has been compared with nimodipine (although intravenous rather than oral) demonstrating improved outcome. A large multicenter study is yet to be conducted.

Cilostazol, a phosphodiesterase 3 inhibitor is a platelet aggregation inhibitor, which also has an effect on smooth muscle cells. Cilostazol has been shown to ameliorate vasospasm in experimental models. Two RCTs were conducted evaluating the use of cilostazol in SAH. One study demonstrated a benefit on DCI and outcome at discharge. The second study showed a reduction in the risk of vasospasm and cerebral infarction, without improvements in outcome. In a meta-analysis, which additionally included two non-RCT, a benefit on outcome at discharge was demonstrated (also when the non-RCT studies were excluded). Importantly, only one study reported long-term outcomes, which did not differ between groups.

Endothelins, potent vasoconstrictors, have been implicated in CVS. An endothelin A receptor antagonist, clazosentan has been shown in experimental as well as clinical studies to ameliorate vasospasm. However, in a large multicentre, phase III study, no improvement in outcome could be shown. Similarly to nicardpine, patients receiving the drug suffered from a large number of systemic complications.

Local delivery
Administration of drugs targeting vasospasm is frequently hampered by systemic complications, a factor that has generated interest in local delivery methods. At present, the only locally delivered substance for which clinical data exist is nicardipine administered into the subarachnoid spaces as prolonged-release implants. Preliminary data comes from an open-label trial in Japan (n=97), where a decrease of the incidence of DCI was noted from 11% to 6%. Subsequently, in a single centre RCT (n=32), nicardipine implants were found to significantly decrease the incidence of vasospasm (73% vs 7%), delayed infarcts (47% vs 14%), as well as improved outcome (38% vs 6%). Notably, the study was conducted only on poor-grade SAH patients, hence, the generalisability and robustness of the results remains uncertain. Currently, no phase III study has confirmed the significance of the initial findings.

Prophylactic balloon angioplasty has not been shown in a multicentre phase II study to be beneficial following SAH. Therapeutic balloon angioplasty and intra-arterial vasodilators, while used in some patients when medical management has failed, are only now being studied in a randomised trial—Diagnostic and Therapeutic Management of Cerebral Vasospasm After Aneurysmatic Subarachnoid Haemorrhage (IMCVS) (clinicaltrials.gov; NCT01400360).

Drugs with multidirectional effects/neuroprotection
Statins, which have been shown to have diverse clinical effects, have been evaluated in four single-centre RCTs with mixed results. A meta-analysis of the trials has so far demonstrated no benefit from using this treatment. However, a multicentre study of simvastatin is currently ongoing (clinicaltrials.gov; NCT00731627), with another one comparing high dose vs low dose (clinicaltrials.gov; NCT01077206). Interestingly, statins have been shown to reduce the duration of impaired autoregulation after SAH, which has been implicated as a potential mechanism of action.
Magnesium is another compound with neuroprotective effects which has been assessed in SAH.\(^{194}\) The interest in magnesium sparked from an observation that hypomagnesemia may be associated with increased incidence of DCI.\(^ {195}\) However, the results from the largest multicentre study and a meta-analysis failed to demonstrate a significant difference in outcome.\(^ {196}\)

The neuroprotective effects of erythropoietin (EPO) have been studied in experimental models.\(^ {197} \)\(^ {198}\) Furthermore, EPO has been shown to ameliorate vasospasm and improve outcome after experimental SAH.\(^ {199}\) Tseng\(^ {200}\) in a single-centre study demonstrated that, similar to statins, EPO treatment was associated with a reduced duration of impaired autoregulation, a lower incidence of severe vasospasm and DCI, as well as an improved outcome at discharge. However, long-term benefits were not demonstrated.

Albumin, 25%, has been shown to be neuroprotective.\(^ {201}\) A pilot study of human albumin demonstrated a good tolerability. Results from phase III RCT are awaited.

Microthrombosis

The findings that SAH leads to clotting activation (physiological mechanism to prevent rebleeding), platelet aggregation and microthrombosis lead to design of studies of antiplatelet agents. Nevertheless, despite solid pathophysiological background, the results of the studies have been largely negative.\(^ {15}\)\(^ {13}\) Similarly, the role of low molecular weight heparin in the prevention of microthrombosis has been investigated in two RCTs. Results of the studies were mixed, with one demonstrating a lack of effect on outcome and four cases of intracranial bleeding thought to be related to the treatment.\(^ {202}\) By contrast, another study found a beneficial effect of enoxaparin on vasospasm, DCI as well as outcome, with fewer haemorrhagic complication in the treated group.\(^ {203}\) However, the results need to be treated with caution, as groups were not well matched for admission grade.

Free radicals and inflammation

Tirilizad mesylate, a non-glucocorticoid, 21-aminosteroid that inhibits lipid peroxidation, has been evaluated in four RCTs with mixed results.\(^ {204} \)\(^ {207}\) However, two meta-analyses demonstrated no effect on DCI, infarcts, or outcome.\(^ {208} \)\(^ {209}\)

Three studies investigated the effect of free radical scavengers on DCI and outcome after SAH.\(^ {210} \)\(^ {211}\)\(^ {212}\) Ebselen was found to improve outcome in a large study of 286 patients. Interestingly, the improvement in outcome was independent of the incidence of DCI which was unchanged between the treatment and placebo groups.\(^ {211}\) Similarly, two other free-radical scavengers, nicaraven and edaravone, have been proven to be beneficial, after SAH.\(^ {210} \)\(^ {212}\)

Several anti-inflammatory compounds have been studied after SAH. Suzuki,\(^ {213}\) used a synthetic thromboxane synthetase inhibitor, OKY-046, to prevent DCI. They demonstrated reduction of DCI and improvement in outcome at 1 year.\(^ {213}\) Methylprednisolone, a strong immunosuppressant, was shown in a randomised study to significantly improve outcome without any effect on vasospasm.\(^ {214}\)

Despite these promising results, none of the investigated compounds have been assessed in multicenter studies nor implemented in clinical practice.

CONCLUSIONS

Outcome form SAH has improved in the last 20 years. This is most likely due to early aneurysm repair, intensive management, and routine use of nimodipine. However, the exact influence of management of DCI on outcome is unclear. This is further complicated by the wide differences in the incidence of DCI, with some studies suggesting an incidence around 15–20%, while others as high as 40%. Despite new data and increased understanding of the pathophysiology of SAH, DCI as well as EBI, no new treatments have been introduced since nimodipine. Data from large randomised controlled studies suggests that a pure focus on CVS, as the sole cause of DCI and poor outcome, is misguided. Nevertheless, the available data does not yet support other approaches aimed at mechanisms distinct form vasospasm, such as microthrombosis and platelet aggregation, inflammation and formation of free radicals. Consequently, current management strategies frequently focus on intensive care management with widespread use of pharmacological and interventional rescue therapies. While numerous targets are still being investigated, some of the more promising results come from drugs with multifactorial effects, such as statins or cilostazol. Overall, available data suggests that a focus on a single pathway may not be sufficient to improve outcomes in SAH. Furthermore, design of future clinical trials should take notice of the available findings and construct studies with appropriate selection of high-risk patients, as well as adequately sensitive and objective outcome measures. Similarly, studies which failed to demonstrate outcome benefits, where sound physiological data exist, should be re-evaluated with the aim of explaining the reason for futility, helping to define the patient groups which could benefit as well as provide background for future drug development.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Cerebrovascular disease


J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2014-307711 on 20 May 2014. Downloaded from http://jnnp.bmj.com/ on April 19, 2022 by guest. Protected by copyright.


Cerebrovascular disease


**Supplemental table 1** Summary of the pathophysiological mechanisms implicated in DCI

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>N</th>
<th>Finding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cortical spreading depolarizations (CSD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Dreier et al.\(^\text{152}\) | 2006 | 18 | 72% of patients exhibited CSD  
Clinical DCI was time correlated with clusters of CSD (PPV 86% and NPV 100%)  
CSD of more than 10 min were associated with delayed infarcts |
| Bosche et al.\(^\text{154}\)    | 2010 | 9  | 89% of patients exhibited CSD  
53% of CSD showed spatial and temporal correlation with PbtO2 response.  
70% of monophasic PbtO2 decreases associated with CSD were seen in in patients who developed DCI  
Hypoxic responses to CSD were augmented in clusters of CSD. |
| Woitzik et al.\(^\text{153}\)   | 2012 | 13 | 77% of patients exhibited CSD |
Significantly more CSD were seen in patients with DCI vs. without DCI (8.7 vs. 1.1)

5/8 patients with CSD developed DCI (3 of these patients had no vasospasm on imaging)

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>N</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sakowitz et al.</td>
<td>2013</td>
<td>17</td>
<td>In patients without acute ischemic deficits clusters of CSD were associated with a decrease in brain glucose and increase in brain lactate. Number of clusters were associated with outcome at 6 months (r=0.659)</td>
</tr>
</tbody>
</table>

**Loss of cerebral autoregulation (AR)**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>N</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pickard et al.</td>
<td>1980</td>
<td>20</td>
<td>0.7% of patients with intact AR developed DCI vs. 80% with disturbed AR who developed DCI</td>
</tr>
<tr>
<td>Lam et al.</td>
<td>2000</td>
<td>20</td>
<td>Patients with primary impairment of AR (n = 5) and CVS (n = 6) developed DCI No patients without primary impairment of AR (n = 14) developed DCI</td>
</tr>
<tr>
<td>Lang et al.</td>
<td>2001</td>
<td>20</td>
<td>88% of patients with intact dynamic AR had good outcome</td>
</tr>
<tr>
<td>Reference</td>
<td>Year(s)</td>
<td>Sample Size</td>
<td>Findings</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>-------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| Tseng et al. 164-166 | 2005, 2006, 2007 | 80 | Disturbed AR was predictive of GOS 1 and 2  
Shorter duration of AR impairment was associated with lower incidence of DCI in pravastatin group  
Treatment with pravastatin, however, had no effect on outcome at 6 months |
| Jaeger et al. 110-111 | 2007, 2012 | 67 | Impaired AR on day 5-6 post SAH was an independent predictor of delayed infarction in poor grade patients  
(p=0.003)  
Impaired AR was an independent predictor of outcome at 6 months |
| Budohoski et al. 161 | 2012 | 98 | Impaired autoregulation was an independent predictor of DCI when both poor and good grade patients were included.  
NPV for development of DCI when multimodal assessment of DCI was performed was 95% |
| Eide et al. 163 | 2012 | 94 | Impaired cerebrovascular reactivity in the 1st week post-ictus was related to outcome at 6 months. |

**Microvascular spasm**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Year</th>
<th>Sample Size</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yundt et al. 132</td>
<td>1998</td>
<td>48</td>
<td>Loss of vasodilatatory ability of parenchymal vessels in patients after SAH compared with controls</td>
</tr>
<tr>
<td>Authors</td>
<td>Year</td>
<td>Volume</td>
<td>Study Details</td>
</tr>
<tr>
<td>------------------</td>
<td>------</td>
<td>--------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Okhuma et al.</td>
<td>2000</td>
<td>24</td>
<td>Prolonged peripheral cerebral circulation time was related to a reduced cerebral blood flow, even in the absence of vasospasm ($r=-0.767$)</td>
</tr>
<tr>
<td>Pennings et al.</td>
<td>2004</td>
<td>16</td>
<td>Direct observations during surgery using orthogonal polarization spectral imaging showed increased contractility of parenchymal arterioles in patients with SAH compared with controls.</td>
</tr>
<tr>
<td>Udoetuk et al.</td>
<td>2007</td>
<td>135</td>
<td>Microvascular cerebral circulation time measured within 24h post-ictus was longer in patients who developed DCI than in those who did and in control</td>
</tr>
<tr>
<td>Microthrombosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suzuki et al.</td>
<td>1990</td>
<td>6</td>
<td>Autopsy revealed fibrin microthrombi related to the sites of delayed infarctions in patients in whom DCI was present</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Negligible microthrombi were seen in patients without DCI</td>
</tr>
<tr>
<td>Ohkuma et al.</td>
<td>1991</td>
<td>13</td>
<td>Increased platelet activation in patients with DCI. Increases in activation occur after DCI onset</td>
</tr>
<tr>
<td>Dorhout Mees et al.</td>
<td>2003</td>
<td>699</td>
<td>Systematic review of 4 studies revealed that administration of antiplatelet medications after SAH reduces the relative risk of DCI (but not poor outcome)</td>
</tr>
<tr>
<td>Author et al.</td>
<td>Year</td>
<td>Page</td>
<td>Summary</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
<td>------</td>
<td>---------</td>
</tr>
<tr>
<td>Stein et al.</td>
<td>2006</td>
<td>29</td>
<td>Autopsy revealed a significant association between microclot burden and symptoms of DCI and histological evidence of ischemia</td>
</tr>
<tr>
<td>Frijns et al.</td>
<td>2006</td>
<td>86</td>
<td>Levels of sP-selectine increased in patients with DCI (n=30) compared with those without DCI (n=56). Increases in sP-selectin occur after DCI onset</td>
</tr>
<tr>
<td>Romano et al.</td>
<td>2008</td>
<td>40</td>
<td>Embolic signals on TCD were associated with symptoms of ischemia and they were often present in spastic vessels</td>
</tr>
</tbody>
</table>

**Inflammation**

<table>
<thead>
<tr>
<th>Author et al.</th>
<th>Year</th>
<th>Page</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryba et al.</td>
<td>1991</td>
<td>25</td>
<td>In a randomized trial patients receiving cyclosporine A had significantly better outcome at discharge compared with controls (p=0.04)</td>
</tr>
<tr>
<td>Manno et al.</td>
<td>1997</td>
<td>9</td>
<td>Non-randomized study showed no effect on prevention of DCI in high risk patients with cyclosporin A.</td>
</tr>
<tr>
<td>Fassbender et al.</td>
<td>2001</td>
<td>35</td>
<td>Significantly higher IL-1β and IL-6 concentration in CSF in patients with SAH vs. controls. Increases occur around day 5 post-ictus and parallel changes in cerebral blood flow velocity.</td>
</tr>
<tr>
<td>Lim et al.</td>
<td>2012</td>
<td>39</td>
<td>Myeloperoxidase levels increased in patients who developed symptomatic vasospasm compared with those who did</td>
</tr>
</tbody>
</table>
In 66.7% of patients with vasospasm myeloperoxidase levels were increased on the day or before development of vasospasm.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>n</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fischer et al.</td>
<td>2013</td>
<td>20</td>
<td>Increased levels of matrix metalloproteinases 3 and 9 after SAH</td>
</tr>
</tbody>
</table>

AR – autoregulation; CSD – cortical spreading depression; CSF – cerebro-spinal fluid; DCI – delayed cerebral ischemia; GOS – Glasgow Outcome Scale; NPV – negative predictive value; PPV – positive predictive value; SAH – subarachnoid haemorrhage; TCD – transcranial Doppler;
### Supplemental Table 2: Summary of studies investigating treatment of DCI

<table>
<thead>
<tr>
<th>Target</th>
<th>Author</th>
<th>Treatment</th>
<th>Study</th>
<th>N</th>
<th>Major Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vasospasm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CSF clearance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Al-Tamimi et al. 2012</td>
<td>LD</td>
<td>RCT</td>
<td>105/105</td>
<td>Significant reduction in the incidence of DCI in LD group. Improved mRS at day 10, but not at 6 months.</td>
</tr>
<tr>
<td>IT thrombolitics</td>
<td>Kanamura et al. 1993</td>
<td>UK/TPA</td>
<td>RCT</td>
<td>51/53</td>
<td>No significant benefit of cisternal irrigation with thrombolitics over cisternal drainage and irrigation with saline</td>
</tr>
<tr>
<td>Study</td>
<td>Region</td>
<td>Drug Formulation</td>
<td>Study Design</td>
<td>Sample Size</td>
<td>Outcomes</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>--------------</td>
<td>-------------</td>
<td>----------</td>
</tr>
<tr>
<td>Findlay et al. 1995</td>
<td></td>
<td>TPA</td>
<td>RCT</td>
<td>50/50</td>
<td>No significant benefit on DCI nor outcome</td>
</tr>
<tr>
<td>Hamada et al. 2003</td>
<td>UK</td>
<td>RCT</td>
<td>57/53</td>
<td>Significant reduction in DCI (OR 0.27) and GOS 1-3 at 6 months (OR 0.32)</td>
<td></td>
</tr>
<tr>
<td>Li et al. 2005</td>
<td>UK</td>
<td>RCT</td>
<td>68/66</td>
<td>Significant reduction in DCI (OR 0.25) and reduction in poor outcome using the Chinese Outcome Scale (OR 0.30)</td>
<td></td>
</tr>
<tr>
<td>Hanggi et al. 2009</td>
<td>UK (with IA nimodipine)</td>
<td>RCT</td>
<td>9/11</td>
<td>No difference in incidence of DCI and outcome.</td>
<td></td>
</tr>
<tr>
<td>Kramer et al. 2011</td>
<td>IT thrombolitics</td>
<td>MA</td>
<td>232/233</td>
<td>Significant reduction in DCI (OR 0.54) and GOS 1-3 at 6 months (OR 0.52). However, after exclusion of one study (where IT nimodipine was administered) none of the results were statistically significant.</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Treatment</td>
<td>Study Design</td>
<td>Outcome</td>
<td>Findings</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Allen et al. 1983</td>
<td>Nimodipine (PO)</td>
<td>RCT</td>
<td>56/60</td>
<td>Significant reduction in DCI</td>
<td></td>
</tr>
<tr>
<td>Philippon et al. 1986</td>
<td>Nimodipine (PO)</td>
<td>RCT</td>
<td>31/39</td>
<td>Significant reduction in DCI</td>
<td></td>
</tr>
<tr>
<td>Neil-Dwyer et al. 1987</td>
<td>Nimodipine (PO)</td>
<td>RCT</td>
<td>75</td>
<td>Significant reduction in mortality</td>
<td></td>
</tr>
<tr>
<td>Jan et al. 1988</td>
<td>Nimodipine (IV)</td>
<td>RCT</td>
<td>73/54</td>
<td>Significantly reduced mortality rate due to severe vasospasm</td>
<td></td>
</tr>
<tr>
<td>Petruk et al. 1988</td>
<td>Nimodipine (PO)</td>
<td>RCT</td>
<td>72/82</td>
<td>Significant improvement in DCI and outcome at 3 months. No effect on cerebral vasospasm.</td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>Drug</td>
<td>Study Design</td>
<td>N</td>
<td>Results</td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------------</td>
<td>--------------</td>
<td>----</td>
<td>----------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Pickard et al. 1989</td>
<td>Nimodipine (PO)</td>
<td>RCT</td>
<td>278/276</td>
<td>Significant reductions in DCI and poor clinical outcome (by 34% and 40% respectively)</td>
<td></td>
</tr>
<tr>
<td>Ohman et al. 1991</td>
<td>Nimodipine (IV)</td>
<td>RCT</td>
<td>104/109</td>
<td>Significant reductions in DCI, delayed infarcts and mortality</td>
<td></td>
</tr>
<tr>
<td>Karinen et al. 1999</td>
<td>Nimodipine (IV)</td>
<td>RCT</td>
<td>62/65</td>
<td>Cost-effective increase in life expectancy (223 USD/year gained)</td>
<td></td>
</tr>
<tr>
<td>Haley et al. 1993</td>
<td>Nicardipine (IV)</td>
<td>RCT</td>
<td>449/457</td>
<td>Significantly decreased incidence of incidence without improvement in outcome</td>
<td></td>
</tr>
<tr>
<td>Shibuya et al. 1992</td>
<td>Fasudil (IV)</td>
<td>RCT</td>
<td>131/136</td>
<td>Significant reductions in vasospasm, DCI, infarcts and poor outcome</td>
<td></td>
</tr>
<tr>
<td>Barker et al. 1996</td>
<td>CCB</td>
<td>MA</td>
<td>1202</td>
<td>Significant reductions in DCI and mortality rate with improved clinical outcomes</td>
<td></td>
</tr>
<tr>
<td>Feigin et al. 1998</td>
<td>CCB</td>
<td>MA</td>
<td>2756</td>
<td>CCBs reduce the RR of poor outcome and DCI;</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Treatment</td>
<td>Study Design</td>
<td>Sample Size</td>
<td>Findings</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>-------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Rinkel et al. 2005</td>
<td>CCB</td>
<td>MA</td>
<td>2844</td>
<td>CCBs reduce the RR of poor outcome (RR 0.82). Oral nimodipine RR 0.70.</td>
<td></td>
</tr>
<tr>
<td>Dorhout Mees et al.</td>
<td>CCB</td>
<td>MA</td>
<td>3361</td>
<td>CCBs decreased the RR of poor clinical outcome, with nimodipine having the largest impact</td>
<td></td>
</tr>
<tr>
<td>Shaw et al. 2000</td>
<td>TAK-044</td>
<td>RCT</td>
<td>207/195</td>
<td>No difference in the incidence of DCI. No improvement in outcome.</td>
<td></td>
</tr>
<tr>
<td>Vajkoczy et al. 2005</td>
<td>Clazosentan</td>
<td>RCT</td>
<td>15/17</td>
<td>Significant reduction in vasospasm. Clazosentan demonstrated reversal of vasospasm in crossover placebo patients</td>
<td></td>
</tr>
<tr>
<td>Macdonald et al. 2008</td>
<td>Clazosentan</td>
<td>RCT</td>
<td>313/100</td>
<td>Significant dose-dependent reductions in moderate and severe vasospasm with increased pulmonary complications, hypotension, and</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Drug(s)</td>
<td>Design</td>
<td>N</td>
<td>Outcome Notes</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-------------</td>
<td>--------</td>
<td>---</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Macdonald et al. 2011\textsuperscript{25}</td>
<td>Clazosentan</td>
<td>RCT</td>
<td>768/389</td>
<td>No difference in all-cause mortality and vasospasm related morbidity at 6 weeks. NO difference in outcome at 6 months.</td>
<td></td>
</tr>
<tr>
<td>Macdonald et all 2012\textsuperscript{26}</td>
<td>Clazosentan</td>
<td>RCT</td>
<td>382/189</td>
<td>Only patients treated with endovascular coiling recruited. Significant reduction in all-cause mortality, vasospasm and vasospasm related rescue therapy and DCI. No effect on outcome.</td>
<td></td>
</tr>
<tr>
<td>Ma et al 2012\textsuperscript{27}</td>
<td>ET-1 antagonists</td>
<td>MA</td>
<td>1679//879</td>
<td>Significant reduction in angiographic spasm and DCI with a trend towards reduced incidence of delayed cerebral infarctions but not reaching significance. No effect on mortality and outcome.</td>
<td></td>
</tr>
<tr>
<td>Niu et al. 2013\textsuperscript{28}</td>
<td>Cilostazol</td>
<td>MA</td>
<td>154/186</td>
<td>Significant reduction of DCI, delayed infarcts and improvement in outcome on discharge</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>Study Authors</td>
<td>Treatment</td>
<td>Study Design</td>
<td>N</td>
<td>Outcome</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>---</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Local administration</td>
<td>Barth et al. 2007</td>
<td>NPRI</td>
<td>RCT</td>
<td>16/16</td>
<td>Significantly improved mRS and NIHSS scores at 1 year</td>
</tr>
<tr>
<td></td>
<td>Zwienenberg-Lee et al. 2008</td>
<td>TBA</td>
<td>RCT</td>
<td>85/85</td>
<td>Significant reduction in need for therapeutic angioplasty. No change in outcome.</td>
</tr>
<tr>
<td>Neuroprotection</td>
<td>Veyna et al. 2002</td>
<td>Magnesium (IV)</td>
<td>RCT</td>
<td>20/16</td>
<td>Trend toward improved MCA TCD velocities and GOS scores (NS)</td>
</tr>
<tr>
<td></td>
<td>van den Bergh et al. 2005</td>
<td>Magnesium (IV)</td>
<td>RCT</td>
<td>139/144</td>
<td>Decreased incidence of DCI (NS) and poor clinical outcome (NS)</td>
</tr>
<tr>
<td>Study</td>
<td>Treatment</td>
<td>Study Design</td>
<td>Participants</td>
<td>Key Findings</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>Wong et al. 2006</td>
<td>Magnesium (IV)</td>
<td>RCT</td>
<td>30/30</td>
<td>Significant reductions in symptomatic vasospasm and duration of elevated TCD velocities; no difference in clinical outcomes</td>
<td></td>
</tr>
<tr>
<td>Muroi et al. 2008</td>
<td>Magnesium (IV)</td>
<td>RCT</td>
<td>31/27</td>
<td>Improved outcome at 3 months</td>
<td></td>
</tr>
<tr>
<td>Wong et al. 2010</td>
<td>Magnesium (IV)</td>
<td>RCT</td>
<td>169/158</td>
<td>No effect on DCI and outcome</td>
<td></td>
</tr>
<tr>
<td>Dorhout Mees et al</td>
<td>Magnesium (IV)</td>
<td>RCT/MA</td>
<td>606/597</td>
<td>No effect on outcome: RR 1.03 for poor outcome in Mg group</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MA (n=2047) showed no improvement in outcome: RR 0.96 for poor outcome in Mg group</td>
<td></td>
</tr>
<tr>
<td>Springborg et al.</td>
<td>Erythropoietin</td>
<td>RCT</td>
<td>36/37</td>
<td>No difference in outcome</td>
<td></td>
</tr>
<tr>
<td>2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tseng et al. 2009</td>
<td>Erythropoietin</td>
<td>RCT</td>
<td>40/40</td>
<td>Significant reductions in severe vasospasm and DCI with improved outcomes at discharge</td>
<td></td>
</tr>
<tr>
<td>EBI</td>
<td>Microthrombosis</td>
<td>Authors</td>
<td>Year</td>
<td>Drug</td>
<td>Type</td>
</tr>
<tr>
<td>-----</td>
<td>----------------</td>
<td>--------</td>
<td>------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mednelow et al.</td>
<td>1982</td>
<td>Acetylosalicylic acid</td>
<td>RCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ono et al.</td>
<td>1984</td>
<td>Ticlopidine</td>
<td>RCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shaw et al.</td>
<td>1985</td>
<td>Dipyridamole</td>
<td>RCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suzuki et al.</td>
<td>1989</td>
<td>OKY-046</td>
<td>RCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tokiyoshi et al.</td>
<td>1991</td>
<td>OKY-046</td>
<td>RCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hop et al.</td>
<td>2000</td>
<td>Acetylosalicylic acid</td>
<td>RCT</td>
</tr>
<tr>
<td>Authors</td>
<td>Year</td>
<td>Treatment</td>
<td>Design</td>
<td>Subjects</td>
<td>Outcome Description</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------</td>
<td>----------------------------------</td>
<td>---------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>van den Bergh et al.</td>
<td>2006</td>
<td>Acetylsalicylic acid</td>
<td>RCT</td>
<td>87/74</td>
<td>No effect on outcome.</td>
</tr>
<tr>
<td>Dorhout Mees et al.</td>
<td>2012</td>
<td>Antiplatelets</td>
<td>MA</td>
<td>743/642</td>
<td>A trend towards a reduction in poor outcome and DCI but NS. Ticlopidine demonstrated a significant reduction in unfavourable outcome (not replicated)</td>
</tr>
<tr>
<td>Siironen et al.</td>
<td>2003</td>
<td>Enoxaparin</td>
<td>RCT</td>
<td>85/85</td>
<td>No difference in 3-month clinical outcome</td>
</tr>
<tr>
<td>Wurm et al.</td>
<td>2004</td>
<td>Enoxaparin</td>
<td>RCT</td>
<td>57/60</td>
<td>Significant reductions in DCI</td>
</tr>
<tr>
<td><strong>Inflammation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suzuki et al.</td>
<td>1989</td>
<td>Thromboxane synthetase inhibitor</td>
<td>RCT</td>
<td>172/86</td>
<td>Significant reductions in vasospasm incidence and DCI (non-dose dependent)</td>
</tr>
<tr>
<td>Study (Year)</td>
<td>Intervention</td>
<td>Design</td>
<td>Phase</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>--------------</td>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Ryba et al. 1991</td>
<td>Cyclosporine A</td>
<td>RCT</td>
<td>9/16</td>
<td>Improved outcome at discharge in treated group.</td>
<td></td>
</tr>
<tr>
<td>Gomis et al. 2010</td>
<td>Methylprednisolone</td>
<td>RCT</td>
<td>49/46</td>
<td>Significant improvement in outcome at 1 year (Functional Outcome Scale). No change in incidence of vasospasm</td>
<td></td>
</tr>
<tr>
<td><strong>Free radicals</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asano et al. 1996</td>
<td>Free radical scavenger (nicaraven)</td>
<td>RCT</td>
<td>74/73</td>
<td>Significant reductions in DCI and mortality rate with significantly improved 1-month outcomes</td>
<td></td>
</tr>
<tr>
<td>Saito et al. 1998</td>
<td>Antioxidant (ebselen)</td>
<td>RCT</td>
<td>145/141</td>
<td>Significant improvement in clinical outcome. No difference in DCI</td>
<td></td>
</tr>
<tr>
<td>Munakata et al. 2009</td>
<td>Free radical scavenger (edaravone)</td>
<td>RCT</td>
<td>49/42</td>
<td>Significant reductions in delayed infarcts and vasospasm related poor outcome at 3 months.</td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>Study Description</td>
<td>Drug</td>
<td>Study ID</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>--------------------------</td>
<td>----------</td>
<td>----------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Jang et al. 2009</td>
<td>Tirilazad mesylate</td>
<td>MA</td>
<td>3797</td>
<td>Reduction of DCI. No effect on outcome</td>
<td></td>
</tr>
<tr>
<td>Zhang et al. 2010</td>
<td>Tirilazad mesylate</td>
<td>MA</td>
<td>3821</td>
<td>Reduction of DCI. No effect on outcome</td>
<td></td>
</tr>
</tbody>
</table>

CCB – calcium channel blockers; DCI – delayed cerebral ischaemia; GOS – Glasgow Outcome Scale; IA – intraarterial; IT – intrathecal; IV – intravenous; LD – lumbar drainage; MA – meta-analysis; MCA – middle cerebral artery; mRS – modified Rankin Scale; NIHSS – National Institute to Health Stroke Scale; NPRI – nicardipine prolonged release pallets; NS – non significant, RCT – randomised controlled trial; RR- -relative risk; SAH – subarachnoid haemorrhage; TBA – transluminal balloon angioplasty; TCD – transcranial Doppler; TPA – tissue plasminogen activator; UK - urokinase


